The FET-Open call of the European Commission finances disruptive innovation research projects capable of « changing the world ». We did not need it any less, so we submitted today a nomination file within the NanoStress consortium, in order to obtain the Proof of Efficiency of our technology, that is to say to prove the action of a stress field on human pancreatic cancer grafted in mouse pancreas. We pursue two parallel objectives. At a minimum, reduce significantly the volume of tumors, to prove we can make human patients operable – this would affect 30% of today incurable patients. At best, we succeed in restoring the cancerous tissue in a normal architecture, transforming malignant tumors into benign tumors.

NanoStress consists of the following entities:

  • INSERM is Principal Investigator. The team of Prof. Alain Couvineau will be responsible for conducting animal experiments in their CRI unit at Bichat Hospital in Paris (France), which will, hopefully, lead to the proof of concept of our technology.
  • CC & C will be in charge of two important aspects: the setting up of the field gradient generator which will apply to the mice a powerful magnetic field gradient, of the order of 50T / m; and the communication around the results at each stage of the process. In addition, Dr. Rémy Brossel, our CSO, will participate in the exploitation of all results and in the writing of subsequent articles.
  • AP-HP (France), in the person of Professor Anne Couvelard and her team, will be in charge of the histology of the tumors at the end of the treatment, in connection with the CRI laboratory.
  • The University of Mons (Belgium), represented by Professor Sophie Laurent and his team, will manufacture and test the vectorized nanoparticles that will be fixed around the tumor and transform the magnetic energy provided by the magnetic field gradient into mechanical pressure.
  • The University of Patras (Greece) is represented by Professor Sophia Antisimiaris and her team. It will open a new path: bring the nanoparticles around the tumor in liposomes, that is to say, small bags of microscopic fat, and no longer just intravenously. The challenge is to bring as much iron as possible and stay there as long as possible.
  • INSERM-Transfert (France), in the person of Delphine Smagghe, will provide project management and coordination with the European Commission.

Our work will take place over two years.

The schedule is as follows: first response within three to five months; if the answer is positive, contracting during the autumn of 2018, and beginning of work in January-February 2019.

 

Addendum of October 20th: We have not been selected by the jury of FET-Open. Nevertheless, we achieved good results, and agreed with the other members of the consortium to present a reworked dossier for the January 2019 session.